China-based diagnostic specialist Shuwen Biotech Co., Ltd announced that its wholly-owned German subsidiary, Cerca Biotech GmbH, has entered into a promotion agreement with Japanese firm Sysmex Corporation’s German unit, Sysmex Europe SE. Under the terms of the deal, Sysmex will promote and distribute Cerca’s MammaTyper, a breast cancer detection product designed for more objective and accurate molecular typing of breast cancer, including the accurate evaluation of HER2 low tumors and Ki-67 markers. The agreement covers 13 countries in Europe, with no further financial details disclosed.
Enhancing Breast Cancer Detection in Europe
MammaTyper, developed by Cerca Biotech, is set to expand its reach in the European market through this partnership with Sysmex Europe. The product offers a significant advancement in breast cancer detection, providing more precise molecular typing and evaluation, which is crucial for patient diagnosis and treatment planning.
Shuwen Biotech’s Commitment to Diagnostic Innovation
Founded in 2011, Shuwen Biotech boasts over 100 diagnostic patents and offers multiple best-in-class diagnostic products and services. Its Guanz Diagnostic Laboratories, a third-party independent medical laboratory, holds accreditation from the College of American Pathologics (CAP), reflecting the company’s commitment to high standards in medical diagnostics.-Fineline Info & Tech
